Abstract

Pancreatic cancer is the leading cause of cancer death worldwide with a poor survival rate. The objective of this study was to determine the mechanism of action of a novel antimitotic and Stat3 inhibitor, LTP-1, on human pancreatic cancer in vitro and in vivo. We found that LTP-1 inhibited pancreatic cancer cell growth and viability with significant G2/M arrest and disruption of microtubule dynamics. LTP-1 also caused G2/M arrest-independent Stat3 dephosphorylation along with ERK activation, which indicated the possible dual function of LTP-1. Long-term treatment of LTP-1 also induced polyploidy, activated caspases, induced subG1 cell population, and therefore, triggered pancreatic cancer cell apoptosis. Finally, we used an in vivo xenograft model to demonstrate that LTP-1 suppressed the growth of pancreatic adenocarcinoma. In summary, our data suggest that LTP-1 may alter microtubule dynamics, which ultimately causes polyploidy and apoptosis, thereby inhibiting pancreatic cancer growth in vitro and in vivo. This study provides evidence that LTP-1 could be a potential therapeutic agent for further development of pancreatic cancer treatment.

Original languageEnglish
Article number27794
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - Jun 9 2016

Fingerprint

Antimitotic Agents
Pancreatic Neoplasms
Polyploidy
Microtubules
Growth
Apoptosis
Caspases
Heterografts
In Vitro Techniques
Pancreatic Carcinoma
Cause of Death
Cell Survival
Adenocarcinoma
Survival Rate
Population
Neoplasms

ASJC Scopus subject areas

  • General

Cite this

LTP-1, a novel antimitotic agent and Stat3 inhibitor, inhibits human pancreatic carcinomas in vitro and in vivo. / Huang, Han Li; Chao, Min Wu; Chen, Chung Chun; Cheng, Chun Chun; Chen, Mei Chuan; Lin, Chao Feng; Liou, Jing Ping; Teng, Che Ming; Pan, Shiow Lin.

In: Scientific Reports, Vol. 6, 27794, 09.06.2016.

Research output: Contribution to journalArticle

@article{73b277fcdecb43708e0daef2d9132690,
title = "LTP-1, a novel antimitotic agent and Stat3 inhibitor, inhibits human pancreatic carcinomas in vitro and in vivo",
abstract = "Pancreatic cancer is the leading cause of cancer death worldwide with a poor survival rate. The objective of this study was to determine the mechanism of action of a novel antimitotic and Stat3 inhibitor, LTP-1, on human pancreatic cancer in vitro and in vivo. We found that LTP-1 inhibited pancreatic cancer cell growth and viability with significant G2/M arrest and disruption of microtubule dynamics. LTP-1 also caused G2/M arrest-independent Stat3 dephosphorylation along with ERK activation, which indicated the possible dual function of LTP-1. Long-term treatment of LTP-1 also induced polyploidy, activated caspases, induced subG1 cell population, and therefore, triggered pancreatic cancer cell apoptosis. Finally, we used an in vivo xenograft model to demonstrate that LTP-1 suppressed the growth of pancreatic adenocarcinoma. In summary, our data suggest that LTP-1 may alter microtubule dynamics, which ultimately causes polyploidy and apoptosis, thereby inhibiting pancreatic cancer growth in vitro and in vivo. This study provides evidence that LTP-1 could be a potential therapeutic agent for further development of pancreatic cancer treatment.",
author = "Huang, {Han Li} and Chao, {Min Wu} and Chen, {Chung Chun} and Cheng, {Chun Chun} and Chen, {Mei Chuan} and Lin, {Chao Feng} and Liou, {Jing Ping} and Teng, {Che Ming} and Pan, {Shiow Lin}",
year = "2016",
month = "6",
day = "9",
doi = "10.1038/srep27794",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - LTP-1, a novel antimitotic agent and Stat3 inhibitor, inhibits human pancreatic carcinomas in vitro and in vivo

AU - Huang, Han Li

AU - Chao, Min Wu

AU - Chen, Chung Chun

AU - Cheng, Chun Chun

AU - Chen, Mei Chuan

AU - Lin, Chao Feng

AU - Liou, Jing Ping

AU - Teng, Che Ming

AU - Pan, Shiow Lin

PY - 2016/6/9

Y1 - 2016/6/9

N2 - Pancreatic cancer is the leading cause of cancer death worldwide with a poor survival rate. The objective of this study was to determine the mechanism of action of a novel antimitotic and Stat3 inhibitor, LTP-1, on human pancreatic cancer in vitro and in vivo. We found that LTP-1 inhibited pancreatic cancer cell growth and viability with significant G2/M arrest and disruption of microtubule dynamics. LTP-1 also caused G2/M arrest-independent Stat3 dephosphorylation along with ERK activation, which indicated the possible dual function of LTP-1. Long-term treatment of LTP-1 also induced polyploidy, activated caspases, induced subG1 cell population, and therefore, triggered pancreatic cancer cell apoptosis. Finally, we used an in vivo xenograft model to demonstrate that LTP-1 suppressed the growth of pancreatic adenocarcinoma. In summary, our data suggest that LTP-1 may alter microtubule dynamics, which ultimately causes polyploidy and apoptosis, thereby inhibiting pancreatic cancer growth in vitro and in vivo. This study provides evidence that LTP-1 could be a potential therapeutic agent for further development of pancreatic cancer treatment.

AB - Pancreatic cancer is the leading cause of cancer death worldwide with a poor survival rate. The objective of this study was to determine the mechanism of action of a novel antimitotic and Stat3 inhibitor, LTP-1, on human pancreatic cancer in vitro and in vivo. We found that LTP-1 inhibited pancreatic cancer cell growth and viability with significant G2/M arrest and disruption of microtubule dynamics. LTP-1 also caused G2/M arrest-independent Stat3 dephosphorylation along with ERK activation, which indicated the possible dual function of LTP-1. Long-term treatment of LTP-1 also induced polyploidy, activated caspases, induced subG1 cell population, and therefore, triggered pancreatic cancer cell apoptosis. Finally, we used an in vivo xenograft model to demonstrate that LTP-1 suppressed the growth of pancreatic adenocarcinoma. In summary, our data suggest that LTP-1 may alter microtubule dynamics, which ultimately causes polyploidy and apoptosis, thereby inhibiting pancreatic cancer growth in vitro and in vivo. This study provides evidence that LTP-1 could be a potential therapeutic agent for further development of pancreatic cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=84973891632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973891632&partnerID=8YFLogxK

U2 - 10.1038/srep27794

DO - 10.1038/srep27794

M3 - Article

C2 - 27278358

AN - SCOPUS:84973891632

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 27794

ER -